drugset

drugset / Trial / NCT04632862

The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.

NCT04632862 ↗

Phase 3 Completed 140 enrolled Daewoong Pharmaceutical Co. LTD.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.

Timeline

Start: 2020-11-11
Primary completion: 2021-11-25
Completion: 2021-11-25

Publications

Kwak SH, Han KA, Kim ES, Choi SH, Won JC, Yu JM, Oh S, Yoo HJ, Kim CH, Kim KS, Chun S, Kim YH, Cho SA, Kim DH, Park KS. Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trial. Diabetes Obes Metab. 2024 Oct;26(10):4203-4212. doi: 10.1111/dom.15738. Epub 2024 Jul 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Enavogliflozin	Small molecule	0.3 mg	Oral

Indications